Installed capacity
Seven production lines, one site
Annual installed capacity at 300 production days a year, company-confirmed in September 2026, with dedicated oncology lines kept separate from the general lines.
-
18.3 M
肿瘤水针制剂产量（支/年）
-
12 M
肿瘤冻干制剂产量（支/年）
-
240 M
肿瘤片剂及胶囊产量（单位/年）
-
21.6 M
普通水针制剂产量（支/年）
-
67.8 M
普通冻干制剂产量（支/年）
-
60 M
Propofol产量（支/年）
-
360 K
吸入剂产量（瓶/年）
By capability
Four ways into the plant
Manufacturing is the base capability everything else builds on; lyophilization is the specialization behind Naprod's oncology injectables; R&D covers formulation and analytical development. Quality & Regulatory governs what the plant is permitted to ship, and where.
-
Manufacturing
The Tarapur, Maharashtra production floor behind the 200+ product catalog across finished dose forms and APIs, run under EU-GMP and WHO-GMP process controls.
-
Lyophilization
Freeze-drying at commercial scale: 12M dedicated oncology vials and 67.8M general vials a year, the capability most closely tied to Naprod’s oncology franchise.
-
Research & Development
Formulation and analytical development behind the catalog and the 24-product official pipeline, feeding future filings across SRA, ROW, and domestic markets.
-
Quality & Regulatory
15+ international accreditations on the register, including EU-GMP, WHO-GMP, ANVISA, INVIMA, EAEU, UAE MOHAP, and NHRA Bahrain.